Osimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit compared to osimertinib alone, according to research presented at the 2023 World Conference on Lung Cancer in Singapore.
Osimertinib, a potent third-generation EGFR-TKI with central nervous system activity, has garnered attention for its targeted inhibition of both sensitizing and resistance EGFR mutations. According to Dr. Jänne, The FLAURA2 trial builds on the favorable results observed in the phase III FLAURA trial, where osimertinib displayed superiority over comparator EGFR-TKIs.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Taiwan's lung cancer early detection program detects 85% of lung cancer cases at early phaseThe Taiwan National Lung Cancer Early Detection Program detected 85% of lung cancer cases at either a phase 0 or phase 1 level, demonstrating that lung cancer screening can detect lung cancer at an early enough phase to allow doctors to intervene more effectively.
Source: medical_xpress - 🏆 101. / 51 Read more »
Osimertinib plus chemotherapy shows significant PFS benefit in advanced EGFR-mutated NSCLCOsimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit compared to osimertinib alone, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Source: NewsMedical - 🏆 19. / 71 Read more »
Taiwan National Lung Cancer Early Detection Program offers hope for saving lives through early diagnosisThe Taiwan National Lung Cancer Early Detection Program detected 85 percent of lung cancer cases at either a phase 0 or phase 1 level, demonstrating that lung cancer screening can detect lung cancer at an early enough phase to allow doctors to intervene more effectively.
Source: NewsMedical - 🏆 19. / 71 Read more »
Study provides new hope for patients with stage III EGFR-mutant non-small cell lung cancerThe immunotherapy drug, durvalumab, has been the standard of care for patients with stage III non-small cell lung cancer(NSCLC) to improve survival, when prescribed after chemotherapy and radiation therapy.
Source: NewsMedical - 🏆 19. / 71 Read more »
Combination treatment shows benefit for patients with extensive-stage small-cell lung cancerThe combination of benmelstobart, anlotinib, and chemotherapy demonstrated significant benefits compared to placebo and chemotherapy in terms of median progression-free survival and overall survival for patients with extensive-stage small-cell lung cancer.
Source: medical_xpress - 🏆 101. / 51 Read more »
Stigmatization of smoking-related diseases is a barrier to care, and the problem may be on the riseThe stigma that patients face when diagnosed with lung cancer is associated with poorer psychosocial outcomes, including distress and isolation, delayed help-seeking, and concerns about the quality of care, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Source: medical_xpress - 🏆 101. / 51 Read more »